Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Blood (2024) 143 (23): 2401–2413.

https://doi.org/10.1182/blood.2023022540

Published: 2024

Includes: Supplemental data

Journal Articles

Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

Blood (2021) 138 (Supplement 1): 2733.

https://doi.org/10.1182/blood-2021-148481

Published: 2021

Journal Articles

Genomic Analysis of NPM1 Mutation and KMT2A ( MLL )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 4460.

https://doi.org/10.1182/blood-2021-149425

Published: 2021

Journal Articles

Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis

Blood (2021) 138 (Supplement 1): 4447.

https://doi.org/10.1182/blood-2021-149801

Published: 2021

Journal Articles

Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 4464.

https://doi.org/10.1182/blood-2021-148492

Published: 2021

Journal Articles

Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2021-149960

Published: 2021

Journal Articles

Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 2313.

https://doi.org/10.1182/blood-2021-146796

Published: 2021

Journal Articles

Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

Blood (2021) 138 (Supplement 1): 3601.

https://doi.org/10.1182/blood-2021-149483

Published: 2021

Journal Articles

Two -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemiatwo -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemia

Kenshi Suzuki, Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, Hiroshi Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Daisuke Iguchi, Koji Izutsu

Blood (2021) 138 (Supplement 1): 1352.

https://doi.org/10.1182/blood-2021-146744

Published: 2021

Journal Articles

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Blood (2021) 137 (26): 3616–3628.

https://doi.org/10.1182/blood.2020008787

Published: 2021

Includes: Supplemental data

Journal Articles

Interim Analysis of Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study of Patients with AML

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-139147

Published: 2020

Journal Articles

Genetic Features of AML with MLL-Rearrangement and NPM1 Mutation: An Interim-Analysis of HM-Screen-Japan 01

SungGi Chi, MD PhD, Naoko Hosono, MD PhD, Takahiro Yamauchi, MD PhD, Kentaro Fukushima, MD, Hirohiko Shibayama, MD PhD, Seiichiro Katagiri, MDPhD, Akihiko Gotoh, MD PhD, Motohito Okabe, MD, Takanobu Morishita, MD, PhD, Masamitsu Yanada, MD PhD, Kazuhito Yamamoto, MD PhD, Naohito Fujishima, MD PhD, Naoto Takahashi, MD PhD, Reiki Ogasawara, MDPhD, Takeshi Kondo, MD PhD, Yoshikazu Utsu, MD PhD, Nobuyuki Aotsuka, MD, Yoshimasa Kamoda, MD, Kensuke Usuki, MD PhD, Kanenari Takemura, MD, Yasuyuki Nagata, MD PhD, Takaaki Ono, MD PhD, Tsutomu Kobayashi, MD PhD, Junya Kuroda, MD PhD, Hiroto Horiguchi, MDPhD, Satoshi Iyama, MD PhD, Suguru Fukuhara, MD PhD, Koji Izutsu, MD PhD, Makoto Nakamura, MD PhD, Kazuto Togitani, MD, Kensuke Kojima, MD PhD, Kaoru Yamamoto, MD, Yukinori Nakamura, MD, Makoto Yoshimitsu, MD PhD, Kenji Ishitsuka, MD PhD, Kenichi Miyamoto, MD, Yosuke Minami, MDPhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-139240

Published: 2020

Journal Articles

A Phase 1 Study Evaluating Safety and Tolerability of Navitoclax Monotherapy in Japanese Patients with Myeloproliferative Neoplasms

Hirohiko Shibayama, MD PhD, Hirokazu Tanaka, MD PhD, Su-Peng Yeh, MD, Hui-Hua Hsiao, MD, Silpa Nuthalapati, PhD, Kota Ono, PhD, Kotaro Uehara, MS, Sumiko Okubo, MD PhD, Norio Komatsu, MD PhD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-137068

Published: 2020

Journal Articles

ASXL1 Mutations Predict a Poor Response to Darbepoetin Alfa in Anemic Patients with Low-Risk MDS: A Multicenter, Phase II Study

Hitoshi Hanamoto, Yasuyoshi Morita, Motoshi Ichikawa, Yasuhito Nannya, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD, Tomoko Hata, Toshihiro Miyamoto, MD PhD, Hiroshi Kawabata, MD PhD, Kazuto Takeuchi, Hiroko Tanaka, Junji Kishimoto, Satoru Miyano, PhD, Itaru Matsumura, MDPhD, Seishi Ogawa, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD, Kinuko Mitani

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134483

Published: 2020

Journal Articles

Genomic Analysis of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Blood (2020) 136 (Supplement 1): 32–34.

https://doi.org/10.1182/blood-2020-137343

Published: 2020

Journal Articles

Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia

Wataru Munakata, Naohiro Sekiguchi, MD PhD, Rai Shinya, MD,PhD, Kenshi Suzuki, MD PhD, Hiroshi Handa, MD PhD, Hirohiko Shibayama, MD PhD, Tomoyuki Endo, MD PhD, Yasuhito Terui, MD PhD, Noriko Iwaki, MD PhD, Noriko Fukuhara, MD PhD, Hiro Tatetsu, MD PhD, Shinsuke Iida, MD PhD, Takayuki Ishikawa, MD PhD, Ryota Shiibashi, Koji Izutsu, MD PhD

Blood (2019) 134 (Supplement_1): 345.

https://doi.org/10.1182/blood-2019-124614

Published: 2019

Journal Articles

Elevated Serum Soluble Interleukin-2 Receptor Level Is a Useful Prognostic Factor for Disease-Specific Overall Survival in Patients with Newly Diagnosed Follicular Lymphoma before Initiation of Treatment

Blood (2019) 134 (Supplement_1): 3985.

https://doi.org/10.1182/blood-2019-126399

Published: 2019

Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2019) 134 (Supplement_1): 5245.

https://doi.org/10.1182/blood-2019-126455

Published: 2019

Journal Articles

Ectonucleosidase CD39 Is Highly Expressed on ATLL Cells and Suppresses the Immune Response through the Adenosine Pathway

Yasuhiro Nagate, MD, Sachiko Ezoe, MD PhD, Jiro Fujita, MD PhD, Takafumi Yokota, MD PhD, Michiko Ichii, MD PhD, Akira Tanimura, Yukiko Doi, Tomoaki Ueda, Jun Toda, MD, Hirohiko Shibayama, MD PhD, Kenji Oritani, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2018) 132 (Supplement 1): 3720.

https://doi.org/10.1182/blood-2018-99-118555

Published: 2018

Journal Articles

ESAM on the Cells of Endothelial Lineage Plays an Important Role in the Development of Definitive Hematopoiesis

Tomoaki Ueda, Takafumi Yokota, MD PhD, Yoshihiro Uno, Tomoji Mashimo, Takao Sudo, Tomohiko Ishibashi, Yukiko Doi, Yasuhiro Shingai, MD, Akira Tanimura, Michiko Ichii, MD PhD, Sachiko Ezoe, MD PhD, Hirohiko Shibayama, MD PhD, Kenji Oritani, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2018) 132 (Supplement 1): 3848.

https://doi.org/10.1182/blood-2018-99-111491

Published: 2018

NARROW

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

Genomic Analysis of NPM1 Mutation and KMT2A ( MLL )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01

Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis

Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01

Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia

Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Interim Analysis of Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study of Patients with AML

Genetic Features of AML with MLL-Rearrangement and NPM1 Mutation: An Interim-Analysis of HM-Screen-Japan 01

A Phase 1 Study Evaluating Safety and Tolerability of Navitoclax Monotherapy in Japanese Patients with Myeloproliferative Neoplasms

ASXL1 Mutations Predict a Poor Response to Darbepoetin Alfa in Anemic Patients with Low-Risk MDS: A Multicenter, Phase II Study

Genomic Analysis of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia

Elevated Serum Soluble Interleukin-2 Receptor Level Is a Useful Prognostic Factor for Disease-Specific Overall Survival in Patients with Newly Diagnosed Follicular Lymphoma before Initiation of Treatment

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Ectonucleosidase CD39 Is Highly Expressed on ATLL Cells and Suppresses the Immune Response through the Adenosine Pathway

ESAM on the Cells of Endothelial Lineage Plays an Important Role in the Development of Definitive Hematopoiesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only